Foreign pharmaceutical companies deny significant layoffs in China

2013-11-06 source: China industry research network recently reported that two of the world's top ten pharmaceutical companies - MSD and AstraZeneca global layoffs affected China Yesterday, both companies denied plans to slash staff in China, saying that despite the "anti commercial bribery" wave, China is still one of the most important markets for foreign pharmaceutical companies According to media reports, insiders of AstraZeneca, a British pharmaceutical giant, said that the company's early overseas layoffs began to have an impact on China, and the outflow of the company's senior management team was serious On the contrary, AstraZeneca still intends to expand its sales team, even though it has been investigated by the industry and Commerce Department for "compliance" issues Since this year, the Department of digestive and respiratory anesthesia alone has added more than 200 sales personnel, which will be further increased In response, AstraZeneca said that the company did not have any layoff plans in China, and the departure of middle and high-level teams was not true "China is becoming more and more important in the company's business, so our R & D personnel and sales teams in China have increased In the third quarter of this year, the company's business growth in China remained in double digits " Mr moshadong also said that it is uncertain whether the company's global layoff plan involves China At present, the Chinese staff, especially the middle and senior management, are stable.